RCM Technologies, Inc.

RCM Technologies, Inc. (RCMT) Market Cap

RCM Technologies, Inc. has a market capitalization of .

No quote data available.

CEO: Bradley S. Vizi

Sector: Industrials

Industry: Conglomerates

IPO Date: 1983-09-12

Website: https://www.rcmt.com

RCM Technologies, Inc. (RCMT) - Company Information

Market Cap: -|Sector: Industrials

Company Profile

RCM Technologies, Inc. delivers business and technology-focused solutions across the United States, Canada, Puerto Rico, and Serbia. The company organizes its operations into three distinct divisions: Engineering, Specialty Health Care, and Life Sciences and Information Technology. The Engineering division provides diverse services, including project management, design, analytical work, engineer-procure-construct (EPC) services, configuration management, hardware/software validation and verification, quality assurance, technical documentation, manufacturing process optimization, and integrated 3D/BIM design. Within its Specialty Health Care unit, RCM offers both temporary and permanent staffing, executive recruitment, and placement services. These cater to various healthcare domains such as allied health and therapy, correctional healthcare, health information management, nursing, physician and advanced practice roles, school services, and telepractice. The Life Sciences and Information Technology segment concentrates on supplying comprehensive enterprise business solutions, application services, robust infrastructure solutions, strategies for competitive advantage, specialized life sciences offerings, and tailored solutions for other specific vertical markets. RCM Technologies serves a broad spectrum of industries, including aerospace and defense, energy, financial services, healthcare, life sciences, manufacturing and distribution, and technology. Additionally, their clientele extends to educational institutions and governmental bodies. Founded in 1971, RCM Technologies, Inc. is headquartered in Pennsauken, New Jersey.

Analyst Sentiment

83%
Strong Buy

From 2 Active Polls

Consensus Target Matrix

Data feed parsing pending...

Price & Moving Averages

Loading chart...

🎯 Wall Street Analyst Intelligence Report

1-Year structural target targets, chart projections, and sentiment maps.

Average 1Y Target
$29.70
▲ +5.00% Upside
Low Target
$21.22
-25% Risk
Median Target
$28.86
2% Mid
High Target
$35.36
25% Max

Consensus Trend Projection

Trailing closures vs. 12-month metrics map.

Analyst Vote Distribution

Aggregate institutional coverage sentiment weights.

Sentiment volume allocation data unavailable.

Historical valuation matrix unavailable.

📘 Full Research Report

ℹ️

AI-Generated Research: This report is for informational purposes only.

📘 RCM TECHNOLOGIES INC (RCMT) — Investment Overview

🧩 Business Model Overview

RCM Technologies Inc operates in the healthcare revenue cycle management (RCM) ecosystem, helping providers capture, bill, and collect reimbursements with a blend of technology enablement and operational services. The value chain typically spans patient access workflows (eligibility and prior authorization support), clinical documentation/coding enablement, claim submission and adjudication follow-up, and denial management. In practice, RCMT’s output is “financial outcomes” for providers—improved claim accuracy, faster reimbursement cycles, and reduced leakage—delivered through workflows that must fit into each customer’s existing billing stack and EHR-related data flows.

This fit-to-workflow requirement creates practical stickiness: process changes, integration work, and training are hard to unwind, particularly when teams rely on day-to-day operational expertise and standardized performance reporting.

💰 Revenue Streams & Monetisation Model

Revenue is generally monetized through a mix of (1) contract-based managed service fees (often structured per client account scope), (2) transaction- or outcome-linked fees tied to claim handling/capture and resolution activities, and (3) technology-enabled implementation or support services where applicable. The monetisation model tends to be partially recurring because RCM operations are ongoing processes rather than one-time projects.

Margin drivers include operational efficiency (labor productivity, standardization of coding/denial workflows), automation of rules-based steps, and scalable delivery across customer accounts. When RCMT can compress cycle times and improve claim acceptance rates without proportionate cost increases, contribution margins benefit—especially when the company’s process knowledge reduces rework and denial volumes.

🧠 Competitive Advantages & Market Positioning

Primary moat: High switching costs (workflow/data integration + operational know-how). RCM is not plug-and-play. Providers and their revenue teams depend on tight integration with billing systems, claims processes, and documentation conventions. Replacing an RCM vendor requires rebuilding interfaces, revalidating claim logic, retuning denial/appeal playbooks, and re-training staff—creating meaningful switching friction.

Secondary moat: Intangible assets in compliance and payer-facing execution. Healthcare reimbursement is rule-dense and changes with policy and billing standards. Competitive advantage often reflects execution quality: coding/charge capture discipline, claims handling accuracy, and a documented approach to denial and appeal management that reduces avoidable leakage.

  • Competitor 1: R1 RCM — a large-scale RCM services provider with broader outsourcing footprints. RCMT’s competitive focus is more provider-services/technology-enabled execution within the RCM value chain rather than pure scale arbitrage.
  • Competitor 2: Change Healthcare (part of Optum / UnitedHealth ecosystem) — emphasizes technology, connectivity, and revenue integrity tooling. RCMT differentiates through operational delivery and workflow fit rather than relying primarily on platform distribution.
  • Competitor 3: Conifer Health (provider of RCM/BPO services; integrated within UnitedHealth Group) — competes on managed services for billing and denial workflows. RCMT’s positioning centers on specific RCM execution capabilities that reduce leakage and improve cash collection for target provider segments.

Overall, RCMT’s industry positioning benefits from a “stickiness” dynamic: customers are incentivized to retain a vendor that understands their operational specifics and delivers measurable financial outcomes, reducing the probability of churn even when procurement cycles remain competitive.

🚀 Multi-Year Growth Drivers

  • Ongoing pressure to improve provider cash flow and reimbursement reliability. As reimbursement rules evolve and administrative complexity persists, demand for RCM capabilities remains structurally supported.
  • Denial and revenue leakage management remains a persistent cost center. Providers seek systematic reduction in claim denials, underpayments, and rework—supporting continued outsourcing/augmentation of RCM functions.
  • Automation + workflow digitization increases the value of process-rich operators. AI and automation can reduce manual effort, but high-quality outcomes still require domain expertise to configure rules, monitor accuracy, and manage edge cases. Vendors with deep operational playbooks can capture more value from digitization than purely transactional competitors.
  • TAM expansion through provider network complexity. Multi-site operations, payer diversity, and documentation variability drive ongoing needs for specialized RCM execution and integration.

⚠ Risk Factors to Monitor

  • Regulatory and reimbursement policy shifts. Changes in billing standards, documentation expectations, or reimbursement rules can reduce the effectiveness of playbooks and require rapid operational adjustment.
  • Technology disruption and competitive pricing. Automation lowers the cost of some RCM steps, increasing competitive intensity and potentially compressing margins if vendors compete primarily on price.
  • Cybersecurity and protected health information (PHI) exposure. RCM processes involve sensitive data and payer communications, creating material operational and reputational risk from breaches.
  • Customer concentration and contract renewal dynamics. Provider budgets and contracting behavior can shift, impacting retention and growth.
  • Operational execution risk. Sustained performance depends on staffing quality, training, and process discipline; deficiencies can increase denial rates and erode customer trust.

📊 Valuation & Market View

Healthcare IT and RCM services are often valued using EV/EBITDA and P/S frameworks, reflecting the market’s focus on durable cash generation, contract-based revenue characteristics, and operating margin potential. Valuation sensitivity typically tracks:

  • Revenue durability and contract retention (evidence of switching cost/embedded relationships).
  • Unit economics and operating leverage (labor productivity, reduced rework/denials, scalable delivery).
  • Quality and compliance performance (audit outcomes, accuracy metrics, and customer satisfaction/renewal signals).
  • Cyber and regulatory risk profile (risk-adjusted confidence in long-term execution).

In this sector, investors generally pay for a combination of growth visibility and margin durability rather than purely top-line expansion.

🔍 Investment Takeaway

RCM Technologies Inc fits a durable healthcare services profile where high switching costs and process- and compliance-driven intangible assets help sustain customer relationships in an RCM environment characterized by persistent reimbursement complexity. The long-term thesis rests on continued demand for denial and leakage reduction, the ability to extract operating leverage through workflow automation, and maintenance of execution quality amid regulatory change—while managing cyber and competitive pricing risk.


⚠ AI-generated — informational only. Validate using filings before investing.

📊 AI Financial Analysis

Powered by StockMarketInfo
Earnings Data: Q Ending 2026-04-04

"RCMT reported Q1 2026 revenue of $83.0M and net income of $3.84M (EPS $0.50). On a YoY basis (vs Q1 2025), revenue declined to $83.0M from $84.5M (-1.5%) while net income improved to $3.84M from $4.19M (-8.2%). QoQ (vs Q4 2025) revenue decreased to $83.0M from $86.5M (-4.1%), and net income fell to $3.84M from $6.10M (-37.0%). Profitability weakened: gross margin eased to 26.5% from 27.4% QoQ, and net margin contracted to 4.63% from 7.06% QoQ. Cash flow quality appears mixed. Operating cash flow was $2.67M in Q1 2026 versus $11.45M in Q4 2025, yielding free cash flow of $2.67M (no capex). Balance sheet leverage is much lighter than prior periods: total assets were $135.3M and equity was $44.3M; total debt fell materially to $4.75M, with net debt about $2.13M. Total shareholder returns are strong given the stock’s momentum (1Y change +96.3%) and no dividend activity indicated. Analyst valuation data is incomplete (no price targets), but the recent price run suggests expectations for operating durability despite near-term earnings volatility."

Revenue Growth

Neutral

QoQ revenue fell from $86.5M to $83.0M (-4.1%); YoY revenue slightly down from $84.5M to $83.0M (-1.5%), indicating modest top-line softness.

Profitability

Caution

Net margin contracted to 4.63% in Q1 2026 from 7.06% QoQ; net income declined QoQ (-37.0%). YoY net income was lower (-8.2%), showing profitability pressure.

Cash Flow Quality

Neutral

Operating cash flow dropped to $2.67M from $11.45M QoQ. However, with minimal/no capex in the quarter, free cash flow matched OCF ($2.67M). No dividends were paid; buybacks were not reported this quarter.

Leverage & Balance Sheet

Strong

Balance sheet resilience improved sharply: total assets rose slightly to $135.3M, equity increased to $44.3M, and total debt decreased to $4.75M with net debt ~ $2.13M.

Shareholder Returns

Strong

High price momentum: 1Y change +96.3% meaning capital appreciation is the dominant component. Dividend yield is shown as 0 and no buyback activity is indicated in Q1.

Analyst Sentiment & Valuation

Neutral

Price targets were not provided (priceTarget: null), limiting confidence in valuation upside/downside. Prior-quarter valuation ratios suggest the market previously priced earnings growth aggressively.

Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.

Fundamentals Overview

Loading fundamentals overview...

Management presented Q4 and 2026 as stronger (record 2026 engineering backlog; expected highest Q4 gross profit and adjusted EBITDA), and the tone is confident on growth drivers: healthcare penetration, Energy Services execution, and Life Sciences AI/compliance initiatives. However, the Q&A reveals near-term operational pressure points. Cash flow was “disappointing” in Q3 due to administrative collection issues with two large school clients. Healthcare is also carrying a heavy medical-claims overhang—$0.8M over budget in Q3 and $1.8M year-to-date—described as hard to forecast and driven by inflationary hospital/insurance cost pressures. Seasonal forecasting also missed on summer-session demand. Foreign nurse hiring is promising (300+ passed exams; potential 50–60 added if visa dates shift by a few months), but timing is explicitly dependent on visa retrogression—analysts pressed for order-of-magnitude impact and got uncertainty. Energy Services is confident but “don’t get too far over your skis” signals discipline amid active market opportunities.

AI IconGrowth Catalysts

  • Record 2026 engineering backlog (end of October) and increased traction with existing healthcare clients
  • Energy Services: record backlog for 2026 and momentum in integrated engineering + EPC for grid hardening/modernization
  • Aerospace & Defense: momentum in existing programs and awards such as Bell Flight Best New Supplier (2025)
  • Life Sciences: AI-driven computer software validation/equipment qualification partnership to streamline compliance and reduce turnaround times
  • Healthcare: increased penetration with existing K-12 school clients and pipeline for 300+ foreign-trained nurses ready to deploy pending visa timing

Business Development

  • Healthcare: expanding roster of new school partners and broadened commitments from existing school clients (K-12 staffing)
  • Life Sciences: partnering with an AI-driven computer software validation and equipment qualification company (named not provided)
  • Energy Services: deepening strategic partnerships with OEMs to improve procurement agility and mitigate equipment lead time constraints
  • Aerospace & Defense: Bell Flight recognized RCMT as Best New Supplier in 2025

AI IconFinancial Highlights

  • Q3 consolidated gross profit: $19.4M (+8.8% YoY)
  • Q3 adjusted EBITDA: $5.5M vs $5.6M prior year (down 1.4%)
  • Q3 adjusted EPS: $0.42 (flat vs Q3 2024)
  • Healthcare Q3 gross profit: $9.0M vs $8.3M (+8.5%) but gross margin down to 30.0% vs 31.2%
  • Healthcare Q3 revenue: school revenue $24.4M vs $20.2M (+20.7%); non-school revenue $5.6M vs $6.4M (-11.3%)
  • Engineering Q3 gross profit: $6.9M vs $5.9M (+17.3%) but gross margin down to 22.0% vs 24.4%
  • IT/Life Sciences/Data Solutions Q3 gross profit: $3.5M vs $3.7M (-4.2%); gross margin up to 39.5% vs 38.0%
  • Medical claims headwind: SG&A included $0.8M costs over budget in Q3 alone and $1.8M year-to-date
  • Cash flow: CFO said they were disappointed with Q3 cash flow from operations due to administrative collection issues with 2 large school clients
  • Guidance tone: management expects Q4 to deliver highest quarterly gross profit and highest adjusted EBITDA in fiscal 2025

AI IconCapital Funding

  • No explicit buyback dollar amount stated in this transcript
  • Revolver in place; management states it provides ample capacity/financial flexibility
  • Capital allocation context: management referenced prior share repurchases totaling 45% of outstanding shares (current outstanding ~7.4M shares) and average cost ~ $8.50 per share; ability to delever quickly

AI IconStrategy & Ops

  • Healthcare seasonality issue in Q3: softer June/July/August due to fewer students in summer session and unpredictability year-to-year; Q3 recovered in September
  • Medical cost mitigation: long-term measures to reduce medical claims costs; also discussed self-insured strategy
  • Self-insured vs fully insured: company is self-insured (800+ covered lives); management said switching fully insured would be worse at their size
  • Energy Services execution: hybrid resourcing model (domestic + global engineering design centers) and use of 3D BIM/digitalization
  • Engineering mix/gross margin explanation: gross margin variability driven by revenue mix and amount of work performed by subs vs salaried employees; Aerospace lower margin; Industrial Processing randomness due to fixed direct-cost base
  • Life Sciences operating emphasis: dedicated life sciences engineering group and integration of AI-driven compliance; scaling managed service offering

AI IconMarket Outlook

  • Energy Services backlog: Q3 update stated 2026 backlog just over $70M vs $21M backlog for 2025 at the same time last year
  • Q4 expectations: highest quarterly gross profit and highest adjusted EBITDA in fiscal 2025
  • Foreign nurse pipeline timing: CFO expects visa retrogression dates could move in Q4; even with a 3–4 month shift, could bring over 50–60 nurses; 300+ nurses already passed exams and are in the pipeline

AI IconRisks & Headwinds

  • Healthcare medical costs: excess medical costs ~ $1.8M year-to-date with Q3 particularly hard; insurance premiums up significantly in 2025 vs 2024; medical claims difficult to forecast
  • Cash flow risk: administrative collection issues with 2 large school clients caused disappointing operating cash flow in Q3
  • Foreign recruitment execution risk: impact depends on visa retrogression; timing uncertain (management could not predict timing reliably)
  • Healthcare seasonality/revenue risk: July/August revenue lower than expected due to fewer students taking summer session and less staffing need than forecast
  • Industrial Process unit underperformance risk: strategy/personnel changes underway; unit is stable and small and unlikely to move needle, but management acknowledged it 'needs to be on a different trajectory'
  • Engineering margins headwind: YoY gross margin down in engineering and Healthcare (mix effects and sub vs salaried work; Aerospace/Industrial Processing randomness)

Sentiment: MIXED

Note: This summary was synthesized by AI from the RCMT Q3 2025 earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.

Loading financial data and tables...
© 2026 Stock Market Info — RCM Technologies, Inc. (RCMT) Financial Profile